Further prospective longitudinal studies are needed to understand the role of the NGR/BACE1 ratio as a biomarker to improve the classification between non-neurodegenerative forms of MCI, including but not exclusively depression, and early AD. This evidence concerns the gene BACE1 and Alzheimer disease.